Biliary Tumor Market Set to Grow Substantially Through 2032, DelveInsight Projects | Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor

DelveInsight's "Biliary Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Biliary Tumor, historical and forecasted epidemiology as well as the Biliary Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Biliary Tumor, offering comprehensive insights into the Biliary Tumor revenue trends, prevalence, and treatment landscape. The report delves into key Biliary Tumor statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Biliary Tumor therapies. Additionally, we cover the landscape of Biliary Tumor clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Biliary Tumor treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Biliary Tumor space.

To Know in detail about the Biliary Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tumor Market Forecast
https://www.delveinsight.com/sample-request/biliary-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Biliary Tumor Market Report:
• The Biliary Tumor market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2024, Jazz Pharmaceuticals announced that the U.S. FDA has granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL for intravenous administration. This approval is for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC), confirmed by an FDA-approved test.
• In November 2024, CTX-009 is a bispecific antibody designed to inhibit both Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which play essential roles in angiogenesis and tumor vascularization. Preclinical and early clinical research indicate that targeting these pathways simultaneously enhances anti-tumor efficacy across various solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Notably, partial responses have been observed in patients with advanced cancers resistant to standard anti-VEGF therapies. The ongoing COMPANION-002 Phase 2/3 clinical trial is evaluating CTX-009 in combination with paclitaxel versus paclitaxel alone in patients with previously treated, unresectable, advanced, metastatic, or recurrent biliary tract cancers (BTC).
• In April 2024, AstraZeneca has released updated exploratory findings from the TOPAZ-1 Phase III clinical trial, showing that Imfinzi (durvalumab), combined with standard-of-care chemotherapy, provided a long-term overall survival (OS) benefit in patients with advanced biliary tract cancer (BTC) at the three-year mark.
• Chemotherapy regimens currently dominate the market. However, several promising therapies in development, such as CX-4945 and CTX-009, are anticipated to significantly impact the Biliary Tract Cancer treatment landscape during the forecast period (2024-2034).
• In 2023, the United States held the largest share of the Biliary Tract Cancer market in the 7MM, representing nearly 48% of the market, compared to the EU4, the UK, and Japan.
• In 2023, the United States represented approximately 30% of the total incident cases of Biliary Tract Cancer in the 7MM, accounting for the highest number of cases within this region.
• In the United States, the majority of Biliary Tract Cancer cases occur in individuals aged 70-79 years, accounting for approximately 30% of all age-specific cases.
• In the United States, TP53 mutations were the most prevalent among mutation-specific cases of Biliary Tract Cancer in 2023, followed by KRAS mutations.
• Key Biliary Tumor Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc, and others
• Key Biliary Tumor Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
• The Biliary Tumor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Tumor pipeline products will significantly revolutionize the Biliary Tumor market dynamics.

Biliary Tumor Overview
Biliary Tumor refers to abnormal growths that develop in the bile ducts, gallbladder, or liver. These tumors can be benign or malignant, with biliary tract cancers (BTCs) being the most concerning. Cholangiocarcinoma (bile duct cancer) and gallbladder cancer are the most common malignant biliary tumors. Symptoms often include jaundice, abdominal pain, weight loss, and digestive issues. Diagnosis typically involves imaging tests, biopsies, and blood markers. Treatment options may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy, depending on the tumor type and stage. Early detection is crucial for better prognosis and treatment outcomes.

Get a Free sample for the Biliary Tumor Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/biliary-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Tumor Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Biliary Tumor Epidemiology Segmentation:
The Biliary Tumor market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Biliary Tumor
• Prevalent Cases of Biliary Tumor by severity
• Gender-specific Prevalence of Biliary Tumor
• Diagnosed Cases of Episodic and Chronic Biliary Tumor

Download the report to understand which factors are driving Biliary Tumor epidemiology trends @ Biliary Tumor Epidemiology Forecast
https://www.delveinsight.com/sample-request/biliary-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tumor market or expected to get launched during the study period. The analysis covers Biliary Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Biliary Tumor Therapies and Key Companies
• Keytruda (pembrolizumab): Merck Sharp & Dohme
• Imfinzi (durvalumab): AstraZeneca
• Futibatinib (TAS-120): Taiho Oncology
• Melphalan: Delcath Systems
• E7090 (tasurgratinib): Eisai
• TT-00420: TransThera Sciences (Nanjing)
• ARQ 087 (Derazantinib): Basilea Pharmaceutica
• Lenvima (lenvatinib): Eisai and Merck & Co
• Zanidatamab: Zymeworks and BeiGene
• XmAb20717: Xencor, Inc.
• Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.
• CTX-009: Compass Therapeutics
• MEDI5752: AstraZeneca
• Brigimadlin: Boehringer Ingelheim
• ZB131: ZielBio, Inc.
• GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.
• BNT141: BioNTech SE
• SO-C101: SOTIO Biotech
• CT-0508: Carisma Therapeutics Inc
• RAIN-32: Rain Oncology Inc
• AVA6000: Avacta Life Sciences Ltd
• DB-1303: DualityBio Inc.

Discover more about therapies set to grab major Biliary Tumor market share @ Biliary Tumor Treatment Landscape
https://www.delveinsight.com/sample-request/biliary-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Biliary Tumor Market Strengths
• The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.

Biliary Tumor Market Opportunities
• Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.

Scope of the Biliary Tumor Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Biliary Tumor Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc, and others
• Key Biliary Tumor Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
• Biliary Tumor Therapeutic Assessment: Biliary Tumor current marketed and Biliary Tumor emerging therapies
• Biliary Tumor Market Dynamics: Biliary Tumor market drivers and Biliary Tumor market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Biliary Tumor Unmet Needs, KOL's views, Analyst's views, Biliary Tumor Market Access and Reimbursement

To know more about Biliary Tumor companies working in the treatment market, visit @ Biliary Tumor Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/biliary-tumor-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Biliary Tumor Market Report Introduction
2. Executive Summary for Biliary Tumor
3. SWOT analysis of Biliary Tumor
4. Biliary Tumor Patient Share (%) Overview at a Glance
5. Biliary Tumor Market Overview at a Glance
6. Biliary Tumor Disease Background and Overview
7. Biliary Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Biliary Tumor
9. Biliary Tumor Current Treatment and Medical Practices
10. Biliary Tumor Unmet Needs
11. Biliary Tumor Emerging Therapies
12. Biliary Tumor Market Outlook
13. Country-Wise Biliary Tumor Market Analysis (2019-2032)
14. Biliary Tumor Market Access and Reimbursement of Therapies
15. Biliary Tumor Market Drivers
16. Biliary Tumor Market Barriers
17. Biliary Tumor Appendix
18. Biliary Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Biliary Tumor Pipeline https://www.delveinsight.com/report-store/biliary-tumor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Biliary Tumor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Biliary Tumor market. A detailed picture of the Biliary Tumor pipeline landscape is provided, which includes the disease overview and Biliary Tumor treatment guidelines.

Biliary Tumor Epidemiology https://www.delveinsight.com/report-store/biliary-tumor-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Biliary Tumor Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Biliary Tumor epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight:
Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.